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Purpose: HER-2/neu overexpression is documented in some bladder cancers. To our 
knowledge, there are no current studies evaluating urine HER-2/neu levels. Therefore, 
we examined the clinical significance of serum and urine HER-2/neu protein in bladder 
cancer. 
Materials and Methods: Urothelial bladder carcinoma patients (n=38, including 31 
men and 7 women) and healthy controls (n=25, including 20 men and 5 women) were 
included in the study. Urine cytology and serum and urine HER-2/neu levels were meas-
ured before the transurethral resection of bladder tumor procedure. Prognostic factors 
including tumor stage, histologic grade, tumor size, multiplicity, and preoperative 
urine cytology and their association with urinary HER-2/neu were analyzed by simple 
and multiple regression analyses. 
Results: There was no significant difference in serum HER-2/neu between the two 
groups (p=0.489). The mean urinary HER-2/neu was 7,586.82  relative luminescence 
unit (RLU) in bladder cancer patients and 4,245.84 RLU in healthy controls. The mean 
RLU values of urinary HER-2/neu in the bladder cancer patient group were sig-
nificantly higher than in healthy controls (p=0.012). An receiver operating character-
istic curve was generated, and using the cutoff value of ≥4,800 RLU of urinary 
HER-2/neu, 71.1% sensitivity and 84.0% specificity were obtained. Among the clinical 
factors, only positive preoperative urine cytology samples were associated with urinary 
HER-2/neu levels by both simple and multiple regression analyses. 
Conclusions: Bladder cancer patients demonstrated significantly higher urinary 
HER-2/neu than did healthy controls. These findings suggest that urinary HER-2/neu 
may be valuable as a new urinary marker. The application of urinary HER-2/neu needs 
additional investigation.
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INTRODUCTION 
Urothelial carcinoma is the most common malignant blad-
der neoplasm. Molecular therapy targets and molecular 
markers are not consistently identified for urinary tract 
cancers, except for renal cell carcinoma. The human pro-
to-oncogene HER-2/neu (c-erbB2, ErbB-2) is a 185-kilo-
dalton transmembrane receptor tyrosine kinase located at 
chromosome 17q [1]. HER-2/neu protein overexpression 
and HER-2/neu gene amplification were correlated with 
higher histologic tumor grade and primary bladder cancer 
invasiveness in several studies; however, these reports 
used immunohistochemistry, fluorescent in situ hybrid-
ization, or polymerase chain reaction [2-7]. Such methods 
are required for tumor tissue processing. The extracellular 
ligand-binding domain of HER-2/neu is shed into the blood-
stream and can be measured quantitatively. The clinical 
significance of serum HER-2/neu levels has been demon-Korean J Urol 2011;52:815-818
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TABLE 1. The characteristics of the bladder cancer patients
Bladder cancer 
group (n=38)
Muscle-invasive 
Non-muscle-invasive
High-grade
Low-grade
Multiple tumor
Solitary tumor
Large size (≥3 cm)
Small size (＜3 cm)
Preoperative urine cytology (+)
Preoperative urine cytology (-) 
12
26
28
10
10
28
15
23
22
16
TABLE 2. The comparison of patients and controls
Bladder cancer group (n=38) Control group (n=25)
p-value
Mean 95% CI Mean 95% CI
Age (yr)
Serum HER-2/neu (ng/ml)
Urine HER-2/neu (RLU)
69.4
    8.41
7,586.82
65.90-72.30
7.58-9.24
  5,052.20-10,121.42
65.8
    8.56
4,245.84 
60.76-70.84
7.61-9.27
3,948.70-4,542.00
0.53
0.49
  0.012
CI: confidence interal, RLU: relative luminescence unit
strated in breast, lung, colorectal, and gastric cancers 
[8-11]. To our knowledge, however, there are no studies of 
urine HER-2/neu in bladder cancer patients. We therefore 
examined the clinical utility of serum and urine HER-2/neu 
and their association with several clinical prognostic 
factors.  
MATERIALS AND METHODS 
Patients (n=38, 31 men and 7 women) with histologically 
confirmed bladder urothelial carcinoma were identified 
from January 2009 to March 2011 and were included in the 
patient group. Controls included 25 healthy volunteers (20 
men and 5 women). No other malignancies were present 
in either group. This study was performed in accordance 
with the Declaration of Helsinki and was approved by the 
Ethics Committee of our institute. Preoperative urine cy-
tology was performed on bladder cancer patients before the 
transurethral resection of bladder tumor procedure. Blood 
and urine (first voided morning sample) were collected for 
serum and urine HER-2/neu measurements. Samples 
were centrifuged at 1,500xg for 10 minutes at 4
oC and were 
stored in a deep freezer at -80
oC until analyzed. Serum and 
urine HER-2/neu were measured at least twice with the 
Siemens serum Her-2/neu test on the ADVIA Centaur im-
munoassay system (Siemens Healthcare Diagnostics Inc., 
Deerfield, IL, USA), and each mean value was taken to be 
a representative value. 
The differences in HER-2/neu levels between both 
groups were analyzed by using Student’s t-test. The influ-
ence of HER-2/neu on prognostic factors including tumor 
stage (by the UICC 2002 TNM staging system, for muscle 
invasiveness), high histologic grade (2004 World Health 
Organization grading system, for low or high grade), tumor 
size (greater or less than 3 cm), multiplicity, and pre-
operative urine cytology results was also analyzed by using 
simple and multiple regression analysis. Statistical analy-
sis was performed by using SPSS ver. 14.0 (SPSS Inc., 
Chicago, IL, USA). Statistical significance was defined at 
p-values less than 0.05.
RESULTS
The mean age of the bladder patients was 69.4 years (range, 
45 to 82 years), and the mean age of the control population 
was 62.3 years (range, 43 to 83 years). The mean serum 
HER-2/neu in bladder cancer patients was 8.41 ng/ml 
(range, 4.0 to 14.0; standard deviation [SD], ±2.33; 95% 
confidence interval [CI], 7.58-9.24) and that in healthy con-
trols was 8.56 ng/ml (range, 5.1 to 12.5; SD, ±1.93; 95% CI, 
7.61-9.27). There were no significant differences identified 
between the two groups (p=0.489). The mean urinary 
HER-2/neu was 7586.82 relative luminescence unit (RLU; 
range, 2,900 to 38,504; SD, ±7,711.20; 95% CI, 5,052.20- 
10,121.42) in bladder cancer patients and 4,245.84 RLU 
(range, 2,747 to 5,455; SD, ±719.85; 95% CI, 3,948.70- 
4,542.00) in healthy controls. The mean RLU values of uri-
nary HER-2/neu were significantly higher in bladder can-
cer patients than in healthy controls (p=0.012). The brief 
characteristics of patients and comparisons of the groups 
are shown in Tables 1 and 2. 
To evaluate the diagnostic value, an receiver operating 
characteristic curve was generated by using urinary 
HER-2/neu values obtained from 38 bladder cancer pa-
tients and 25 healthy volunteers (Fig. 1). Using the cutoff 
value of ≥4,800 RLU of urinary HER-2/ neu, 71.1% sensi-
tivity and 84.0% specificity were obtained. We examined 
the association of urinary HER-2/neu with muscle in-
vasiveness (vs. non-muscle invasiveness), histologic grade 
(high vs. low grade), tumor size (greater or less than 3 cm), 
multiplicity (vs. solitary mass), and preoperative urine cy-
tology (positive vs. negative). Only positive preoperative 
urine cytology samples were associated with urinary 
HER-2/neu levels by both simple and multiple regression 
analyses (Table 3). Korean J Urol 2011;52:815-818
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FIG. 1. ROC curve for urinary HER-2/neu. Using the cutoff value 
of ≥4,800 RLU of urinary HER-2/neu, 71.1% sensitivity and 
84.0% specificity were obtained. ROC: receiver operating 
characteristic, RLU: relative luminescence unit.
TABLE 3. The characteristics of the bladder cancer patients
Variable
Simple regression Multiple regression
Rp - v a l u e β
R
2=0.281,  
p-value
Muscle invasiveness
WHO grade 3
Large size (≥3 cm)
Multiplicity
Preoperative 
  cytology (+)
 0.21
-0.18
-0.01
 0.07
 0.33
0.074
0.175
0.876
0.670
0.002
 0.12
-0.35
 0.04
 0.16
 0.37
0.665
0.441
0.944
0.540
0.034
WHO: World Health Organization
DISCUSSION
The clinical significance of serum HER-2/neu has already 
been evaluated in prostate, colorectal, and stomach can-
cers; patients with elevated serum HER-2/neu demon-
strate poor survival compared with patients with lower 
HER-2/neu [10,12,13]. Several studies have reported an 
association between prognosis and HER-2/neu oncogene 
overexpression from bladder cancer specimens [5-7,14]. 
Unlike previous studies using bladder cancer tissue, blood 
or urine samples can be collected for measurement of 
HER-2/neu without surgery or biopsy. Proteolytic cleavage 
of the extracellular domain of the HER-2/neu molecule re-
sults in HER-2/neu protein excretion into the blood circu-
lation [15,16]. Preoperative serum and urinary HER-2/neu 
have been measured in gastric and colorectal cancer pa-
tients, and serum HER-2/neu was significantly higher in 
the patient groups [10-12]. Urinary HER-2/neu was sig-
nificantly elevated in gastric cancer patients, although the 
process of urinary HER-2/neu protein excretion is still un-
clear [12]. Ecke et al reported that serum HER-2/neu can 
differ between bladder cancer patients and controls with 
high sensitivity [17]; however, in the present study, we did 
not find a difference between the two groups. Although se-
rum HER-2/neu was not significantly different between 
the bladder cancer and control groups in the present study, 
urinary HER-2/neu was significantly elevated in the blad-
der cancer group. Bladder cancer patient urine typically 
contains tumor cells, red blood cells, and secreted protein, 
which suggests the potential for elevated urinary 
HER-2/neu in cancer patients compared with healthy 
controls. We analyzed the characteristics of patients with 
urinary HER-2/neu, and positive preoperative urine cytol-
ogy samples were associated with high urinary HER-2/neu 
by both simple and multiple regression analyses (Table 3). 
Other clinical data, including muscle invasiveness, high 
histologic grade, tumor size (greater or less than 3 cm), and 
multiplicity were not significantly associated with high 
urinary HER-2/neu levels. The general sensitivity and spe-
cificity of bladder tumor antigen tests, nuclear matrix pro-
tein 22 tests, immunoCyt, and UroVysion are relatively 
high; such tests have been used for bladder cancer screen-
ing and monitoring but are still unsatisfactory compared 
with cytology. The other urinary markers, such as AURKA, 
BLCA-1, BLCA-4, CEACAM1, survivin, and urinary UBC 
test are now investigational, and these urinary markers 
have a relatively high false-positive rate [18]. As another 
urinary marker, urinary HER-2/neu protein showed 71.1% 
sensitivity and 84.0% specificity using the cutoff value of 
≥4,800 RLU. Our study was limited by a small sample size, 
and therefore larger-scale studies are necessary to estab-
lish the usefulness of urinary HER-2/neu measurement. 
Additional studies might reveal associations between se-
rum or urine HER-2/neu in bladder cancer and HER-2/neu 
immunohistochemical staining study, bladder cancer re-
currence, progression, and survival. Further, targeted 
therapy with monoclonal antibodies to the HER-2/neu on-
coprotein, such as trastuzumab in breast cancer patients, 
might be clinically applicable in bladder cancer patients.
CONCLUSIONS
Bladder cancer patients demonstrated significantly high-
er urinary HER-2/neu levels than did healthy controls. 
Urinary HER-2/neu was associated with positive urine cy-
tology samples. These findings suggest that urinary 
HER-2/neu may be valuable as a new urinary marker. 
Additional studies should examine the prognostic sig-
nificance of serum and urinary HER-2/neu. 
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